» Articles » PMID: 25136449

Catecholamine-secreting Carotid Body Paraganglioma: Successful Preoperative Control of Hypertension and Clinical Symptoms Using High-dose Long-acting Octreotide

Overview
Specialty Endocrinology
Date 2014 Aug 20
PMID 25136449
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: A 48-year-old hypertensive and diabetic patient presented with a 10-year history of progressive right facial pain, tinnitus, hearing loss, sweating, and palpitations. Investigations revealed a 5.6 cm vascular tumor at the carotid bifurcation. Her blood pressure (BP) was 170/110, on lisinopril 20 mg od and amlodipine 10 mg od and 100 U of insulin daily. A catecholamine-secreting carotid body paraganglioma (CSCBP) was suspected; the diagnosis was confirmed biochemically by determining plasma norepinephrine (NE) level, 89 000 pmol/l, and chromogranin A (CgA) level, 279 μg/l. Meta-iodobenzylguanidine and octreotide scanning confirmed a single tumor in the neck. A week after giving the patient a trial of octreotide 100 μg 8 h, the NE level dropped progressively from 50 000 to 25 000 pmol/l and CgA from 279 to 25 μg/l. Treatment was therefore continued with labetalol 200 mg twice daily (bid) and long-acting octreotide-LA initially using 40 mg/month and later increasing to 80 mg/month. On this dose and with a reduced labetalol intake of 100 mg bid, BP was maintained at 130/70 and her symptoms resolved completely. CgA levels returned to normal in the first week and these were maintained throughout the 3 month treatment period. During tumor resection, there were minimal BP fluctuations during the 10 h procedure. We conclude that short-term high-dose octreotide-LA might prove valuable in the preoperative management of catecholamine-secreting tumors. To the best of our knowledge, this is the first report on the successful use of octreotide in a CSCBP.

Learning Points: The value of octreotide scanning in the localization of extra-adrenal pheochromocytoma.Control of catecholamine secretion using high-dose octreotide.This is a report of a rare cause of secondary diabetes and hypertension.

Citing Articles

Hypertensive Crisis in a Patient With a Functioning Mesenteric Paraganglioma: Dramatic Response to Octreotide Treatment.

Elshafie O, Bou Khalil A, Alshaibi M, Itkin B, Ismail B, Woodhouse N AACE Clin Case Rep. 2023; 9(5):149-152.

PMID: 37736317 PMC: 10509379. DOI: 10.1016/j.aace.2023.05.003.


Secondary hypertension: An update on the diagnosis and localisation of a pheochromocytoma or paraganglioma.

Siddiqui N, Daya R, Seedat F, Bulbulia S, Bayat Z S Afr Fam Pract (2004). 2021; 63(1):e1-e6.

PMID: 34342483 PMC: 8377944. DOI: 10.4102/safp.v63i1.5277.


68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI.

Janssen I, Chen C, Taieb D, Patronas N, Millo C, Adams K J Nucl Med. 2015; 57(2):186-91.

PMID: 26564322 PMC: 4738157. DOI: 10.2967/jnumed.115.161018.


Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.

Janssen I, Blanchet E, Adams K, Chen C, Millo C, Herscovitch P Clin Cancer Res. 2015; 21(17):3888-95.

PMID: 25873086 PMC: 4558308. DOI: 10.1158/1078-0432.CCR-14-2751.

References
1.
Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M . The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf). 2006; 65(3):287-93. DOI: 10.1111/j.1365-2265.2006.02591.x. View

2.
Duet M, Guichard J, Rizzo N, Boudiaf M, Herman P, Tran Ba Huy P . Are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas?. Laryngoscope. 2005; 115(8):1381-4. DOI: 10.1097/01.MLG.0000165806.99675.A9. View

3.
Schwaber M, Glasscock M, Nissen A, Jackson C, Smith P . Diagnosis and management of catecholamine secreting glomus tumors. Laryngoscope. 1984; 94(8):1008-15. DOI: 10.1288/00005537-198408000-00002. View

4.
Woodhouse N, Dagogo-Jack S, Ahmed M, Judzewitsch R . Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing's syndrome. Am J Med. 1993; 95(3):305-8. DOI: 10.1016/0002-9343(93)90283-u. View

5.
Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S . High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009; 161(2):331-8. DOI: 10.1530/EJE-09-0372. View